Founded in 1834, Tulane is one of the most highly regarded and selective independent research universities in the United States. It is proud to be a member of the prestigious Association of American Universities, a select group of 63 universities with “pre-eminent programs of graduate and professional education and scholarly research.” Tulane’s schools and colleges offer undergraduate, graduate and professional degrees in the liberal arts, science and engineering, architecture, business, law, social work, medicine and public health and tropical medicine.
Featured Startups and Technologies
Acromegaly occurs when the pituitary gland in your body creates too much of substances known as growth hormone and growth factors. SomatulineÃ‚Â® Depot (lanreotide) Injection is a medical treatment for acromegaly that decreases the effects of those substances and helps your body control acromegaly. SomatulineÃ‚Â® Depot (lanreotide) Injection is different from other medical treatments for acromegaly, and the difference is a single, ready-to-use, prefilled syringe with a simple, easy injection procedure. SomatulineÂ® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.
Cetrorelix acetate is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). A synthetic decapeptide, it is used to treat hormone-sensitive cancers of the prostate and breast (in pre-/perimenopausal women) and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, cetrorelix is used in assisted reproduction. The drug works by blocking the action of GnRH upon the pituitary, thus rapidly suppressing the production and action of LH and FSH. It is administered as a daily or weekly subcutaneous injection.
Triptorelin (acetate or pamoate), a decapeptide (pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2), is a gonadotropin-releasing hormone agonist (GnRH agonist). By causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Like other GnRH agonists, triptorelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, precocious puberty, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction. Triptorelin is marketed under the brand names Decapeptyl (Ipsen) and Diphereline and Gonapeptyl (Ferring Pharmaceuticals). In the United States, it is sold by Watson as Trelstar. During the treatment of prostate cancer it does cause a surge of testosterone (an initial uplevel of testosterone levels), known as a flare effect. In men a reduction of serum testosterone levels into the range normally seen after surgical castration occurs approximately two to four weeks after initiation of therapy. In contrast, gonadotropin-releasing hormone antagonists do not cause a surge, but a sudden reduction of testosterone levels.
Office of Technology Transfer and Intellectual Property Development
1430 Tulane Avenue
New Orleans, Louisiana 70112-2632
Phone: (504) 988-6962